The original clinical-development program for sofosbuvir–velpatasvir involved two trials — one in patients with HCV genotype 1, 2, 4, 5, or 6 (ASTRAL-1) and one in patients with HCV genotype 3.

In total, 1208 patients were treated. The rate of sustained virologic response at 12 weeks among genotype 1–infected patients was 99.1% (95% confidence interval [CI], 98 to 100) in the 8-week ...

Hepatitis C virus genotype 1 is the most prevalent genotype and accounts for 83.4 million infections, or 46.2% of all cases, worldwide, according to a study published in Hepatology.

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at ...

Findings indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. Share: Facebook Twitter Pinterest LinkedIN Email.

Final results of phase III trials show that telaprevir plus standard therapy with peginterferon alfa-2a and ribavirin was more effective than standard therapy alone. Recently, telaprevir-based ...

Analysis shows that HCV genotype 1 is the most prevalent at 46% of all HCV cases, followed by genotype 3 at 30%; genotypes 2, 4, and 6 with a combined total of 23% and genotype 5 at less than 1%.

The Food and Drug Administration (FDA) has approved Harvoni (ledipasvir/sofosbuvir; Gilead Sciences), the first once-daily single tablet regimen for the treatment of ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 17, 2012-- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the majority of hepatitis C genotype 1 patients with a prior “null” response to ...

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Harvoni™ (ledipasvir 90 mg/sofosbuvir 40 ...